This is the first oral PCSK9 inhibitor; it cuts LDL cholesterol (or ApoB) levels by 50-60%. It uses a different mechanism than a statin so you can layer them to get an 80% or so reduction overall.

It also reduces Lp(a), the strongest hereditary risk factor for heart disease, by 28%.

Previous PCSK9 inhibitors like Repatha were injectables (similar to GLP-1s). Only about 1% of people eligible for injectable PCSK9 inhibitors use them, so having a convenient daily pill is a potentially huge win for prevention.